Protocol Ledger

NCT06990399 · Phase III · RECRUITING

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK

Interventional Phase III clinical trial protocol NCT06990399 sponsored by Kodiak Sciences in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-07-30 Enrollment: 600 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06990399
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)600 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06990399
Protocol FieldVerified Registry Value
NCT IdentifierNCT06990399
Consolidated Lead SponsorKodiak Sciences
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment600 participants (ESTIMATED)
Registered Start Date2025-07-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI